BeiGene

A World of Difference

Our global philosophy on improving access to innovative medicines

Care beyond medicine

Safe and effective treatments **should be accessible to all**

In recent years, substantial global efforts in research and development have led to the discovery of highly advanced oncology treatments that target tissues, cells, and genes. These new treatments are starting to make a difference, but only for patients who are able to receive them.[1]

We believe the cost of life-saving oncology treatments should never be a barrier to timely access for patients in need. We are dedicated to ensuring that our products are **accessible and affordable**; our goal is to bring the best therapies to the greatest number of patients possible. We believe in:

- Dedicating efforts to areas of **high unmet need**, both clinical and socioeconomic
- Striving to **address affordability challenges** for patients and health systems around the world
- Working in collaboration with stakeholders across the healthcare ecosystem to **improve access to care**

Our access and affordability philosophy begins with the clinical value of our products. This value is supported by our efforts to improve access to care, and our dedication to patients, physicians, and access stakeholders around the world. We believe that **cancer has no borders. Neither do we.**

Proven clinical outcomes.

Broader treatment access.

Advancing global health by putting patients first.

BeiGene

The Elements of Our Story

Compelling Clinical Evidence

Improving Access to Care

OUR DEDICATION TO ONCOLOGY, PATIENTS, AND COLLABORATION

Our access and affordability philosophy is based on robust clinical evidence, improving access to care, and meaningful collaborations that make a difference for patients and access stakeholders around the world.

BeiGene

Compelling Clinical Evidence

Our focus is on **clinical excellence**

Since 2010, our mission has been to build the first next-generation biotechnology company—one that expands the highest-quality therapies to more people around the world — through courage, persistent innovation, and challenging the status quo. We have a strong focus on developing innovative and affordable medicines to improve treatment outcomes for oncology patients worldwide. BeiGene is:

Committed to developing the best and first-in-class clinical candidates around the world

Developing molecularly targeted immuno-oncology and combination therapies

Conducting R&D globally with 90+ clinical trials involving more than 13,000 patients in 45+ geographies*

*As of June 2022.

Conventional clinical trials account for a large majority of the cost and time required to bring most oncology medicines to market. Keeping our rigorous standards of clinical excellence in mind, we have implemented our **own fully integrated infrastructure** designed to uniquely support global clinical trials. Managing trials in-house gives us **significantly better control over quality, speed, and cost,** as well as higher levels of engagement with site investigators.

We prioritize effective treatments for conditions with a **high level of unmet need**



Considering an estimated 19.3 million new cancer cases and almost 10 million cancer deaths in 2020 worldwide,[2] oncology is a therapeutic area in which limited treatment options lead to a persistent unmet need.

Our first priority is to develop therapies that have the greatest potential for positive impact, which is why our broad R&D pipeline covers **80% of the world's cancers by incidence.**

BeiGene

Compelling Clinical Evidence

Well-designed trials **generate valuable data** for access decision-makers

There are multiple ethical and methodological concerns related to placebo-controlled trials, and strong clinical evidence can help ensure that access decision-makers have the information they need to make **informed decisions**. In particular, head-to-head (H2H) studies have been recognized as the gold standard in oncology because they provide the **most direct comparison to existing therapies** and can determine if a treatment is superior to another. That's why our current pivotal trials include **two H2H trials** and two large trials of other BeiGene assets **against established treatments**.[3-6] Furthermore, our ongoing work **generating real-world evidence (RWE) and health economics and outcomes research (HEOR) data** helps support the clinical case for our products.

Studying a diverse patient population is **key to health equity**

Because patients from different backgrounds may have different reactions to the same treatment based on factors such as age, gender, weight, race or ethnicity, we strive to diversify the patient populations represented in our clinical trials. We believe diversity **will improve the quality of the data** that we use to demonstrate that our treatments are safe and effective.



BeiGene clinical trial presence by continent

We seek to develop differentiated treatments that **improve the standard of care**.

BeiGene

Improving Access to Care

We work to broaden access, **one country at a time**

The everyday impact of cancer on the global patient population cannot be underestimated. Beyond immeasurable personal costs to individual patients, evidence suggests that delayed access to oncology treatments might even result in significant potential economic value lost.[1]

We aim to do our part to **address accessibility and affordability challenges** experienced by patients around the world by entering public and private agreements to support broad access. BeiGene has collaborated with health systems in almost 50 countries to accelerate availability of treatments for patients; examples are provided in the following figure.

Increasing Access to Our Medicines

US

We entered the market in 2019 with a BTK inhibitor at a list price 10% below that of the leading competitor

Germany

When our treatment was approved for Waldenstrom's macroglobulinemia (WM), BeiGene entered the market at parity pricing (rather than at a premium) with the leading competitor

China

Three of our products have been added to China's National Reimbursement Drug List (NRDL), which provides broad access at more affordable prices to patients across China

Australia

Following regulatory approval of our treatment for adult patients with mantle cell lymphoma (MCL) and WM, BeiGene accepted the initial reimbursement to avoid protracted negotiation

While many companies first seek approvals in developed markets that can yield the most economic gains, we seek registration of our products across **both developed and developing markets** early in the commercialization process. For example, in 2021, we expanded access to **more than 47 markets, several of which are underserved**, and are actively planning for submissions of FDA-approved indications for WM and marginal zone lymphoma (MZL) in Latin America to quickly provide our treatment to these patients.

Our Commitment to Patients

We are committed to letting **patient needs** guide our priorities

We know accessing medicines and seeking reimbursement is complex and sometimes difficult. To keep patients **first in all we do**, we are intentional in how we provide support to patients and their caregivers. We aim to provide **care beyond medicine** throughout the entire patient journey in a number of ways:

- Low- or no-cost medicines to eligible patients
- Pre-approval and/or compassionate-use programs in certain markets
- Support group information and transportation/lodging assistance arranged through collaboration with charitable organizations
- Patient education and counseling services

MyBeiGene: Complete Commitment to Patients

In the United States and Canada, we established myBeiGene, which provides patients with **reimbursement and coverage support, copay assistance, and free medicine for eligible patients to support access** to our treatments. In addition to reimbursement and financial support, myBeiGene also provides access to oncology nurse advocates to provide personalized support for patients and caregivers—including educational materials and connection with advocacy and support groups.

Whatever your patients' needs, we work to provide solutions. Visit **myBeiGene.com**

CLL Society Diversity, Equity & Inclusion Programs for Patients

In the US, BeiGene is partnering in the CLL Society's robust efforts to ensure that all chronic lymphocytic leukemia (CLL) patients have **equitable access to knowledge and treatment options regardless of race, geography, and socioeconomic factors**. This includes supporting a newly developed Black, Indigenous, and People of Color (BIPOC) resource page on the society's website that promotes resources for minority patients and communities, amplifies awareness of differences in health outcomes, and provides connections to partners addressing health-outcome disparity in rural areas and with identified communities. BeiGene also supports a Spanish-language version of the CLL Society Toolkit, which provides important disease awareness information and resources for patients.

Our Commitment to Oncology

We work with the **best minds in oncology**

8,400+ employees—one of the largest oncology teams in the world—collaborating across 5 continents on an ever-expanding portfolio

11 Internally discovered molecules to clinic in first 10 years

90+ Clinical trials in progress in the US and globally

~50 Molecules at commercial or clinical stage

30+ Phase 3 or potentially registration-enabling trials

50+ Preclinical programs ongoing

>1,800 Clinical scientists working in research and development

Industry partners

SHORELINE Biosciences · MEI Pharma · Bristol Myers Squibb · AMGEN · NOVARTIS · Seagen · HUTCHMED · MIRATI THERAPEUTICS · Ambrx · zymeworks · assemblybio · leaptherapeutics · EUSAPharma · 百奥泰 BIO-THERA · Singlomics 丹序生物 · STRAND THERAPEUTICS · bioatla · BITT

Innovations from our pipeline

BTK inhibitor

Approved in 47 global markets in the US, EU, and China. Indications include MCL, CLL, WM, and MZL

PD-1 inhibitor

Currently studied in lung, liver, gastric, and esophageal cancers and Hodgkin's lymphoma

PARP inhibitor

Approved in China. Indications include ovarian, breast, gastric, and prostate cancers

Other novel agents

Currently studied in cervical cancer, locally advanced and solid tumors, and more

Our world-class research and development team works to uncover a range of **innovative treatments**.

BeiGene

Our Commitment to Collaboration

We work with access stakeholders across the healthcare ecosystem so that our treatments can **reach those in need**



The Access to Oncology Medicines (ATOM) Coalition[7]
It is estimated that less than 50% of the cancer medicines on the WHO Model List of Essential Medicines (WHO EML) are currently available in low- and lower middle-income countries (LLMICs). To address this problem, the Union for International Cancer Control (UICC), along with BeiGene and other partners, has established the ATOM coalition**,** a new global partnership to **increase access to quality-assured essential cancer medicines** in LLMICs and to help countries develop the capacity for their proper use.

The ATOM Coalition partners seek to build a sustainable operating model that facilitates access over time, as breakthroughs occur, to new medicines that can have a significant health impact in LLMICs, while ensuring that today's effective medicines are more widely available across those countries in a sustainable manner.

BeiGene believes in engaging in **meaningful partnerships to support access and affordability.**

This document is intended for a global audience, including payers, policy-makers, patient advocates, and others.

BeiGene

References:

1. The Conference Board of Canada. Tomorrow can't wait: the value of breakthrough cancer treatments for Canadians. Accessed May 16, 2022. https://www.conferenceboard.ca/temp/a7dd7fee-13dc-4a74-a4f2-d0821e459d4a/11451-issue-briefing-tomorrow-cant-wait.pdf **2.** Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021;71:209-249. https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660.
3. ClinicalTrials.gov. A study comparing BGB-3111 and ibrutinib in participants with Waldenström's macroglobunemia (WM)(ASPEN). https://clinicaltrials.gov/ct2/show/NCT03053440?term=ASPEN+BeiGene&draw=2&rank=1. **4.** ClinicalTrials.gov. A study of zanubrutinib (BGB-3111) versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia (ALPINE). https://clinicaltrials.gov/ct2/show/NCT03734016?term=ALPINE+BeiGene&draw=2&rank=1#wrapper. **5.** ClinicalTrials.gov. Comparison of efficacy and safety of anti-PD-1 antibody BGB-A317 versus docetaxel as treatment in the second- or third-line setting in participants with NSCLC. https://clinicaltrials.gov/ct2/show/NCT03358875?term=Tislelizumab%E2%80%8B+Taxotere&draw=2&rank=4. **6.** ClinicalTrials.gov. A study of ociperlimab with tislelizumab compared to pembrolizumab in participants with untreated lung cancer. https://clinicaltrials.gov/ct2/show/NCT04746924?term=ociperlimab&draw=2&rank=7. **7.** Access to Oncology Medicines (ATOM) Coalition press release. May 18, 2022. Geneva, Switzerland.

June 2022